After inking reverse merger, Graphite Bio divests gene editing pipeline to newly-formed biotech

Ka­mau Ther­a­peu­tics has emerged from stealth mode af­ter ink­ing a deal with Graphite Bio for its genome edit­ing as­sets. Ka­mau’s de­but comes less than a month af­ter Graphite en­tered a re­verse merg­er deal with Lenz Ther­a­peu­tics to form a new com­bined com­pa­ny.

San Fran­cis­co-based Ka­mau was co-found­ed by Stan­ford sci­en­tists Maria Grazia Ron­car­o­lo and Matthew Por­teus, who were al­so in­volved in cre­at­ing Graphite. Both re­searchers con­tributed to mak­ing Graphite’s ho­mol­o­gy di­rect­ed re­pair (HDR) plat­form tech­nol­o­gy, which Ka­mau now has the op­tion to ac­quire un­der the terms of the deal, the fi­nan­cial de­tails of which were undis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.